Repertoire®免疫药物与基因泰克达成合作和许可协议，共同开发针对自身免疫疾病的T细胞靶向疗法-动脉网

Repertoire® Immune Medicines Enters into Collaboration and License Agreement with Genentech for the Development of T cell-Targeted Therapies for an Autoimmune Disease

CISION 等信源发布 2025-04-23 19:00



可切换为仅中文







Repertoire will deploy its industry leading DECODE

Repertoire 将部署其行业领先的 DECODE

™

platform to generate target discoveries

生成目标发现的平台

that Genentech will further optimize and translate into new immune medicines

基因泰克将进一步优化并转化为新的免疫药物

Repertoire is eligible to receive

曲目有资格接收

$35M

3500万美元

upfront and up to

预先并高达

$730M

7.3亿美元

in additional milestone

在额外的里程碑

payments, as well as tiered royalties

付款，以及分级版税

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

April 23, 2025

2025年4月23日

/PRNewswire/ -- Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease.

/PRNewswire/ -- Repertoire® Immune Medicines，一家致力于发现和开发可编程T细胞靶向免疫药物的生物技术公司，今天宣布与罗氏集团成员Genentech达成合作和许可协议，以发现和开发用于治疗自身免疫性疾病的创新T细胞靶向免疫药物。

Repertoire will deploy its DECODE™ platform, which uniquely maps the immune synapse, to discover novel therapeutic targets..

Repertoire将部署其DECODE™平台，该平台独特地绘制了免疫突触图谱，以发现新的治疗靶点。

'Repertoire's DECODE™ platform uniquely maps the entire immune synapse in patients and thereby enables development of transformative T cell-targeted medicines for autoimmune diseases and cancer,' said

“Repertoire的DECODE™平台能够独特地绘制患者整个免疫突触图谱，从而推动针对自身免疫疾病和癌症的变革性T细胞靶向药物的开发。”

Torben Straight Nissen

托本·斯特雷特·尼森

, Chairman and CEO of Repertoire and Executive Partner at Flagship Pioneering. 'The enormous breadth of DECODE's therapeutic target discovery potential is well beyond what we could realize on our own. Given Genentech's commitment and experience as the global market leader in developing treatments for autoimmune diseases, we are delighted to partner with them to bring medicines to patients that reset the immune system and have the potential to provide significant therapeutic benefits.'.

Repertoire董事长兼首席执行官，Flagship Pioneering的执行合伙人表示：“DECODE在治疗靶点发现方面的巨大广度远远超出了我们单靠自身所能实现的范围。鉴于Genentech作为全球市场领导者在开发自身免疫疾病治疗方面的承诺与经验，我们非常高兴能与他们合作，为患者带来能够重置免疫系统并有潜力提供显著治疗效益的药物。”

'Roche and Genentech have been investing in breakthrough therapies for autoimmune disorders for more than 20 years, and we are proud of the advances in treatment we have pioneered,' said Boris L. Zaïtra, Head of Roche Corporate Business Development. 'As we seek new opportunities to bring an even greater impact to patients, we look forward to translating the new discoveries DECODE.

“罗氏和基因泰克在自身免疫性疾病突破性疗法方面已经投资了20多年，我们为我们在治疗上开创的进展感到自豪，”罗氏公司业务发展主管鲍里斯·L·扎伊特拉表示。“随着我们寻求新的机会以对患者产生更大的影响，我们期待转化DECODE的新发现。”

™

and the team at Repertoire will reveal to develop novel medicines for patients suffering from autoimmune diseases.'

Repertoire团队将揭示为自身免疫疾病患者开发新型药物的方法。

Under the terms of the agreement, Repertoire will lead target discovery activities using its DECODE

根据协议条款，Repertoire将利用其DECODE平台主导目标发现活动。

™

platform to explore a large antigenic space, and Genentech will be responsible for preclinical and clinical development as well as the global commercialization of innovative therapies that incorporate the target discovery work. Repertoire is eligible to receive

平台探索广阔的抗原空间，而基因泰克将负责临床前和临床开发以及包含靶点发现工作在内的创新疗法的全球商业化。Repertoire有资格获得

$35M

3500万美元

upfront as well as up to

预先以及多达

$730M

7.3亿美元

in additional development, regulatory and commercial milestones, as well as tiered royalties.

此外还有开发、监管和商业里程碑，以及分级特许权使用费。

About Repertoire® Immune Medicines

关于Repertoire®免疫药物

Repertoire Immune Medicines is discovering the unique immune codes that determine how we maintain health and respond to disease. Our proprietary DECODE™ platform uniquely elucidates the entire immune synapse, providing a comprehensive understanding of the interactions between T cell receptors and their cognate antigenic epitopes.

Repertoire Immune Medicines 正在发现决定我们如何保持健康和应对疾病的独特免疫代码。我们专有的 DECODE™ 平台独特地阐明了整个免疫突触，提供了对 T 细胞受体与其同源抗原表位之间相互作用的全面理解。

Repertoire is translating these insights into new and potentially transformative T cell-targeted therapies for the treatment of cancer and autoimmune diseases..

Repertoire正在将这些见解转化为新的、可能具有变革性的T细胞靶向疗法，用于治疗癌症和自身免疫疾病。

Repertoire was founded in 2019 by Flagship Pioneering. Its team operates from sites in

Repertoire 于 2019 年由 Flagship Pioneering 创立。其团队在以下地点开展工作：

Cambridge, Massachusetts

麻萨诸塞州剑桥市

and

和

Zurich

苏黎世

. To learn more about Repertoire, please visit our website:

要了解更多关于Repertoire的信息，请访问我们的网站：

www.repertoire.com